Quantcast

Industry news that matters to you.  Learn more

Archives for June 2015

Genetic Variance Explains Poor Response to Common Asthma Medications

Researchers have identified a biological basis for asthmatic children who do not respond well to corticosteroid treatment – currently the most effective treatment for chronic asthma and acute asthma attack.

PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development

PointCross Life Sciences recently announced a strategic partnership with InterpretOmics Pvt. Ltd. to provide an integrated Big Data and globally accessible environment for genomic interpretation and analysis of all biomarkers collected in the context of clinical trials and nonclinical studies. This platform will serve the needs of precise or multi-targeted drug candidates, stratified patient selection and ex post analysis of efficacy and disease progression free survival.

OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test

OPKO Health, Inc. (NYSE:OPK) recently announced the online publication of a study entitled “Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study” in the Journal of the National Cancer Institute. The study shows that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore® Test (Total PSA, Free PSA, Intact PSA and hK2) accurately identifies risk for aggressive prostate cancer prior to prostate biopsy.

New Study Shows Cleveland HeartLab Inflammation Testing can Prevent Thousands of Heart Attacks and Strokes, Averting $187 Million in Healthcare Costs for Cardiovascular Disease

Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease management company, and MDVIP, the leader in personalized, preventive medicine, are pleased to announce the publication of a seminal peer review study in the Journal of Medical Economics. The study shows that by improving cardiovascular disease risk (CVD) assessment, CHL’s inflammation testing could reduce heart attacks and strokes by nearly 10 percent.

NanoCellect And Invetech Announce Collaboration to Develop Novel Flow Cytometry Platform for Cell Sorting and Analysis

Invetech, a global leader in instrument design and development, custom automation, and contract manufacturing, and NanoCellect Biomedical, a company developing affordable and accessible flow cytometry and cell sorting technology for life science researchers, recently announced a collaboration to develop a novel flow cytometry platform.